This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Posted by Martha Carter, Matt Filosa, andFaten Alqaseer, Teneo, on Sunday, December 15, 2024 Editor's Note: Martha Carter is Vice Chair and Head of Governance Advisory, and Matt Filosa and Faten Alqaseer are Senior Managing Directors, at Teneo. This post is based on a Teneo memorandum by Ms. Carter, Mr. Filosa, Ms. Alqaseer, Kensey Biggs , Diana Lee , and Rose James.
Proposed acquisition strengthens Pharming's late-stage pipeline with a potential first-in-disease asset Abliva's lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved, in mitochondrial DNA-driven primary mitochondrial diseases Total transaction value of approximately US$66.1 million No external funding required to fund acquisition and KL1333 development costs Pharming to host a conference call on Monday, December 16, 2024 at 14:00 CET (
Want to understand the intricacies of service business valuation? Dive into our detailed breakdown to learn how to assess and maximize your companys value! Valuation of Service Business If you own or manage a service-based business, knowing the value of your company is super important! Whether you're thinking about selling, looking for financing, or just want to understand the health of your business, a thorough valuation can offer amazing insights.
Speaker: Susan Spencer, Principal of Spencer Communications
Intent signal data can go a long way toward shortening sales cycles and closing more deals. The challenge is deciding which is the best type of intent data to help your company meet its sales and marketing goals. In this webinar, Susan Spencer, fractional CMO and principal of Spencer Communications, will unpack the differences between contact-level and company-level intent signals.
We today announce the formation of The Shadow SEC, an independent organization of six current academics that, like the earlier established Federal Reserve Shadow Open Market Committee, is intended to provide, encourage, facilitate, and distribute policy discussions and debates relating to the federal securities laws and the Securities and Exchange Commission (SEC).
Westford, USA, Dec. 15, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the global stem cell banking market share will reach a value of USD 18.65 Billion by 2031 , with a CAGR of 18.30% during the forecast period (2024-2031). As cryopreservation and cell bank preparation techniques are getting advanced, the stem cell banking market is expanding rapidly.
The Consumer Financial Protection Bureau (the CFPB) recently released a report identifying limits in federal privacy protections afforded by the Fair Credit Reporting Act (FCRA) and Gramm-Leach-Bliley Act (the GLBA). The report strongly encourages state policymakers to consider how consumers are impacted by the FCRA and GLBA exemptions contained in all of the 19 [1] broad state consumer privacy laws enacted over the past six years.
The Consumer Financial Protection Bureau (the CFPB) recently released a report identifying limits in federal privacy protections afforded by the Fair Credit Reporting Act (FCRA) and Gramm-Leach-Bliley Act (the GLBA). The report strongly encourages state policymakers to consider how consumers are impacted by the FCRA and GLBA exemptions contained in all of the 19 [1] broad state consumer privacy laws enacted over the past six years.
Westford, USA, Dec. 15, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the global healthcare analytical testing services market size will reach a value of USD 15.55 Billion by 2031 , with a CAGR of 11.2% during the forecast period (2024-2031). The market's main driving factors are the number of companies in the pharmaceutical and medical device industries that outsource analytical testing services, increased clinical trials in need of analytical testing, and the rising emphasis on biosimil
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content